Search

Comparison of experiences in two birth cohorts comprising young families with children under four years during the initial Covid-19 lockdown in Australia and the UK: A qualitative study

This study aims to understand the experience and impact of the initial COVID-19 lock-down in young families with children aged below 4 years. Free text questions were administered to participants in the ORIGINS (Australia) and Born in Bradford (UK) cohort studies to collect qualitative information on worries, concerns and enjoyable experiences during the pandemic.

In “high-risk” infants with sufficient vitamin d status at birth, infant vitamin D supplementation had no effect on allergy outcomes: A randomized controlled trial

Early infancy oral vitamin D supplementation does not appear to reduce the development of early childhood allergic disease

Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.

Longitudinal effects of prenatal exposure to plastic-derived chemicals and their metabolites on asthma and lung function from childhood into adulthood

Environmental exposure to phthalates and bisphenol A (BPA), chemicals used in the production of plastics, may increase risk for asthma and allergies. However, little is known about the long-term effects of early life exposure to these compounds.

Personalised, machine learning based prediction of asthma in children

This study aims to show that asthma and allergies in individuals can be predicted before it occurs based on individual family history and information on the early environment.

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

The MELODY Study is a Phase 3 randomized, double-blind, placebo-controlled, single-dose study to determine if MEDI8897 will prevent medically attended Respiratory Syncytial Virus (RSV) -confirmed Lower Respiratory Tract Infection (LRTI) in healthy infants entering their first RSV season.

Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Wildfire smoke exposure during pregnancy and perinatal, obstetric, and early childhood health outcomes: A systematic review and meta-analysis

Maternal exposure to air pollution during pregnancy is associated with adverse birth outcomes, although less is known for wildfire smoke. This systematic review evaluated the association between maternal exposure to wildfire smoke during pregnancy and the risk of perinatal, obstetric, and early childhood health outcomes. 

Wal-yan researchers to join global respiratory congress in Vienna

Researchers from the Wal-yan Respiratory Research Centre are proud to be part of this prestigious event, contributing their expertise to the Congress' outstanding scientific programme.

Seven innovative lung health research projects supported by Wal-yan Centre funding

Seven innovative lung health research projects have received funding support as the 2023 Wal-yan Respiratory Research Centre Strategic Inspiration Projects.